Hervé Bonnefoi
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
Leone J, Vaz-Luis I, Colleoni M, Di Leo A, Goldhirsch A, Wardley A, Bonnefoi H, Láng I, Neven P, Harvey V, Ejlertsen B, Gelber R, Giobbie-Hurder A, Rabaglio M, Coates A, Thürlimann B, Regan M, Cole B, Lin N. Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. Cancer 2020
Dec 8, 2020Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
Dec 8, 2020Cancer 2020
Leone Jose P, Vaz-Luis Ines, Colleoni Marco, Di Leo Angelo, Goldhirsch Aron, Wardley Andrew, Bonnefoi Hervé, Láng István, Neven Patrick, Harvey Vernon J, Ejlertsen Bent, Gelber Richard D, Giobbie-Hurder Anita, Rabaglio Manuela, Coates Alan S, Thürlimann Beat, Regan Meredith M, Cole Bernard F, Lin Nancy U
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Rabaglio M, Thürlimann B, Colleoni M, Goldhirsch A, Gelber R, Coates A, Castiglione M, Ruepp B, Wardley A, Bonnefoi H, Láng I, Neven P, Harvey V, Ejlertsen B, Giobbie-Hurder A, Maibach R, Sun Z, Regan M. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Res Treat 2020
Nov 7, 2020Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Nov 7, 2020Breast Cancer Res Treat 2020
Rabaglio Manuela, Thürlimann Beat, Colleoni Marco, Goldhirsch Aron, Gelber Richard D, Coates Alan S, Castiglione Monica, Ruepp Barbara, Wardley Andrew, Bonnefoi Hervé, Láng István, Neven Patrick, Harvey Vernon J, Ejlertsen Bent, Giobbie-Hurder Anita, Maibach Rudolf, Sun Zhuoxin, Regan Meredith M
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Ruhstaller T, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber R, Coates A, Goldhirsch A, Thürlimann B, Regan M, Veyret C, Del Mastro L, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen E, Gladieff L, Bonnefoi H, Harvey V, Spazzapan S, Tondini C, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol 2018:JCO1800440.
Nov 26, 2018Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Nov 26, 2018J Clin Oncol 2018:JCO1800440
Ruhstaller Thomas, Simoncini Edda, Gianni Lorenzo, Rochlitz Christoph, Kralidis Elena, Zaman Khalil, Jassem Jacek, Piccart-Gebhart Martine, Di Leo Angelo, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Thürlimann Beat, Regan Meredith M, Veyret Corinne, Del Mastro Lucia, Giobbie-Hurder Anita, Colleoni Marco, Jensen Maj-Britt, Ejlertsen Bent, de Azambuja Evandro, Neven Patrick, Láng István, Jakobsen Erik Hugger, Gladieff Laurence, Bonnefoi Hervé, Harvey Vernon J, Spazzapan Simon, Tondini Carlo, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.
Oct 8, 2012Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Oct 8, 2012J Clin Oncol 2012; 30:3967-75
Ewertz Marianne, Goldhirsch Aron, Coates Alan S, Smith Ian E, Láng István, Colleoni Marco, Gelber Richard D, Rabaglio Manuela, Paridaens Robert J, Forbes John F, Bonnefoi Hervé, Thürlimann Beat, Price Karen N, Ejlertsen Bent, Regan Meredith M, Gray Kathryn P, Mouridsen Henning T
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 2011; 131:295-306.
Sep 4, 2011The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Sep 4, 2011Breast Cancer Res Treat 2011; 131:295-306
Chirgwin Jacquie, Coates Alan S, Goldhirsch Aron, Regan Meredith M, Bonnefoi Hervé, Ejlertsen Bent, Thürlimann Beat, Price Karen N, Smith Ian, Sun Zhuoxin, BIG 1-98 Collaborative and International Breast Cancer Study Groups
ASCO 2009: What's New in Breast Cancer Therapy?
Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's New in Breast Cancer Therapy?. Breast Care (Basel) 2009; 4:268-271.
Aug 14, 2009ASCO 2009: What's New in Breast Cancer Therapy?
Aug 14, 2009Breast Care (Basel) 2009; 4:268-271
Biganzoli Laura, Bonnefoi Hervé, Cardoso Fatima, Coleman Robert, Thürlimann Beat
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni M, Hürny C, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Gertsch M, Schmitz S, Siegrist H, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. Breast Cancer Res Treat 2004; 87:75-86.
Sep 1, 2004Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sep 1, 2004Breast Cancer Res Treat 2004; 87:75-86
Sabbioni Marzio E E, Hürny Christoph, Goldhirsch Aron, Herrmann Richard, Perey Lucien, Bonnefoi Hervé, Thürlimann Beat, Gertsch Monica Castiglione, Schmitz Shu-Fang Hsu, Siegrist Hans-Peter, Bernhard Jürg, Swiss Group for Clinical Cancer Research (SAKK)